Spero Therapeutics (NASDAQ:SPRO) Announces Earnings Results, Beats Expectations By $0.01 EPS

Spero Therapeutics (NASDAQ:SPRO) released its earnings results on Monday. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.01, Zacks reports. Spero Therapeutics had a return on equity of 35.42% and a net margin of 21.09%. The firm had revenue of $10.20 million for the quarter, compared to analysts’ expectations of $9.80 million. During the same quarter in the previous year, the business posted ($0.23) EPS.

Spero Therapeutics Stock Down 3.1 %

Shares of NASDAQ SPRO traded down $0.04 during trading hours on Wednesday, hitting $1.23. The company had a trading volume of 159,422 shares, compared to its average volume of 222,329. Spero Therapeutics has a 1-year low of $0.99 and a 1-year high of $1.89. The firm’s 50 day moving average is $1.38 and its 200-day moving average is $1.51. The stock has a market capitalization of $66.41 million, a P/E ratio of 2.97 and a beta of 0.63.

Analyst Ratings Changes

A number of research firms have recently issued reports on SPRO. HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Spero Therapeutics in a report on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Spero Therapeutics in a research note on Tuesday. Finally, TD Cowen upgraded shares of Spero Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.